Novavax reported $-565985000 in Equity Capital and Reserves for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Adma Biologics ADMA:US USD 100.38M 14.02M
Agenus AGEN:US USD -20385000 23.8M
AstraZeneca AZN:LN USD 35.13B 798M
Astrazeneca AZN:US USD 35.13B 798M
Biocryst Pharmaceuticals BCRX:US USD -242659000 29.43M
Genocea Biosciences GNCA:US USD 12.38M 14.69M
Geron GERN:US USD 108.17M 33.88M
GlaxoSmithKline GSK:LN GBP 9.15B 7.22B
Mannkind MNKD:US USD -237677000 9.38M
Minerva Neurosciences NERV:US USD -14246000 5.86M
Moderna Inc MRNA:US USD 17.99B 7M
Novartis NVS:US USD 60.82B 2.1B
Novavax NVAX:US USD -565985000 149.04M
Pain Therapeutics PTIE:US USD 198.72M 19.65M
Peregrine Pharmaceuticals PPHM:US USD 179M 4.47M
Sarepta Therapeutics SRPT:US USD 430.84M 295.62M
Tg Therapeutics TGTX:US USD 100.48M 28.55M